AbbVie, Teva must face US antitrust case over Niaspan, judge concludes
MLex Summary: AbbVie and Teva Pharmaceuticals failed to win summary judgment in a US case accusing them of conspiring to delay generic Niaspan. “We conclude that the undisputed evidence shows that the settlement...To view the full article, register now.
Already a subscriber? Click here to view full article